FDA Approves Jaguar Health’s Plant-Based Therapy For Chemo-Induced Diarrhea In Dogs
The FDA has granted conditional approval for Jaguar Health Inc's (NA
Jaguar Health Confirms Earlier Reports Of FDA Conditional Approval Of Canalevia-CA1
Jaguar Health, Inc. (NASDAQ:JAGX) today announced it received conditional approval to market Canalevia™-CA1 (crofelemer delayed-release tablets), Jaguar's oral plant-based prescription drug for the
Jaguar Health Shares Move Higher; Traders Circulate Application For Conditional Approval For Co’s CANALEVIA-CA1 Crofelemer Delayed-Release Tablets For Dogs
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11727
European Medicines Agency Grants Orphan Drug Designation For Crofelemer To Napo EU, Jaguar Health’s Italian Subsidiary, For Short Bowel Syndrome
The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company's exclusive license agreement with Jaguar Health
SAN FRANCISCO, CA
Jaguar Health Highlights Presentation Of Findings From Investigator-Initiated Phase 2 HALT-D Study Of Crofelemer For Prevention Of Chemo-Induced Diarrhea In Breast Cancer Patients At San Antonio Breast Cancer Symposium
Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients
SAN FRANCISCO, CA /
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours.